Granocyte
Generic Name
Lenograstim (rDNA origin)
Manufacturer
Chugai Pharmaceutical Co., Ltd.
Country
Japan
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| granocyte 34 miu injection | ৳ 7,687.00 | N/A |
Description
Overview of the medicine
Lenograstim is a recombinant human granulocyte colony-stimulating factor (rHuG-CSF) that stimulates the proliferation, differentiation, and function of neutrophil precursors. It is used to reduce the duration of neutropenia and its associated complications following cytotoxic chemotherapy, bone marrow transplantation, or in congenital/idiopathic neutropenias.
Uses & Indications
Dosage
Adults
Usually 150 mcg (19.2 MIU)/m² (or 5 mcg/kg) daily via subcutaneous injection or intravenous infusion. Dosage and duration depend on the specific indication, patient's body weight, and neutrophil response. For PBPC mobilization, it can be 10 mcg/kg/day.
Elderly
No specific dosage adjustment is generally required for elderly patients, but careful monitoring of renal and hepatic function is recommended.
Renal_impairment
Dosage adjustment is generally not required, but cautious use and monitoring are recommended in patients with severe renal impairment due to limited data.
How to Take
Administered by subcutaneous injection or intravenous infusion. Subcutaneous route is generally preferred for long-term self-administration.
Mechanism of Action
Lenograstim binds to specific receptors on myeloid progenitor cells, stimulating their proliferation, differentiation, and functional activation into mature neutrophils, thereby increasing neutrophil counts.
Pharmacokinetics
Onset
Neutrophil count increase typically observed within 24-48 hours of administration.
Excretion
Renal excretion of metabolites.
Half life
Approximately 3-4 hours after subcutaneous administration; 1-1.5 hours after intravenous administration.
Absorption
Subcutaneous (SC) administration: good bioavailability (30-70%). Peak plasma concentrations reached within 3-5 hours. Intravenous (IV) administration: immediate and complete bioavailability.
Metabolism
Primarily metabolized by proteolytic degradation and subsequently eliminated by the kidneys. Also cleared by target cells (neutrophils).
Side Effects
Contraindications
- Hypersensitivity to lenograstim or any component of the formulation.
- Patients with myeloid malignancies where G-CSF might stimulate tumor growth (e.g., chronic myeloid leukemia, myelodysplastic syndrome), unless used for PBPC mobilization for autologous stem cell transplant.
Drug Interactions
Lithium
May potentiate the myeloproliferative effects of lenograstim, increasing neutrophil counts. Monitor neutrophil levels closely if co-administered.
5-Fluorouracil
Not to be administered within 24 hours of cytotoxic chemotherapy (especially 5-Fluorouracil) due to potential for exacerbating myelosuppression.
Storage
Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the pre-filled syringe in the outer carton to protect from light.
Overdose
The effects of an overdose are not fully characterized. Management involves supportive care and monitoring of peripheral blood counts, especially neutrophil counts. Discontinuation of therapy generally leads to a return to baseline counts.
Pregnancy & Lactation
Pregnancy Category C. Should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. It is unknown whether lenograstim is excreted in human breast milk, so caution is advised during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months when stored as recommended.
Availability
Available in hospitals and specialized pharmacies
Approval Status
Approved by major regulatory bodies (e.g., EMA, DGDA)
Patent Status
Patent expired, generic versions available
Clinical Trials
Extensively studied in numerous clinical trials demonstrating efficacy in reducing neutropenia duration and complications in patients undergoing chemotherapy and bone marrow transplantation, as well as in PBPC mobilization.
Lab Monitoring
- Complete Blood Count (CBC) with differential, especially neutrophil counts.
- Platelet counts and hemoglobin levels.
- Regular monitoring of splenic size (if appropriate).
Doctor Notes
- Monitor CBC with differential regularly during therapy.
- Assess splenic size periodically, especially in patients with chronic neutropenia.
- Educate patients on symptoms of splenic rupture (left upper abdominal pain) and allergic reactions.
- Avoid concomitant administration with cytotoxic chemotherapy within 24 hours.
Patient Guidelines
- Do not shake the syringe vigorously.
- Store in the refrigerator (2-8°C). Do not freeze.
- Report any unusual pain (especially in the upper left abdomen) immediately to your doctor.
- Learn proper subcutaneous injection technique if self-administering.
Missed Dose Advice
If a dose is missed, contact your doctor for advice. Do not take a double dose to make up for a forgotten dose.
Driving Precautions
Granocyte has no direct influence on the ability to drive and use machines. However, if you experience dizziness or fatigue, avoid driving or operating machinery.
Lifestyle Advice
- Maintain good hygiene to reduce infection risk, especially during neutropenia.
- Avoid crowded places and contact with people who are sick during periods of low white blood cell count.
- Follow your doctor's dietary recommendations.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.